mRNA Vaccines: Current Status & Future Prospects

Pallavi Dikole[1], Abhishek Kamble[2]
[1,2]*K. T. Patil College of Pharmacy, Dharashiv*

***Abstract*—mRNA-based vaccines have transformed the field of vaccinology by enabling rapid design and swift updates against newly emerging viruses. Compared with older vaccine platforms, they drive a potent "dual arm" immune response, stimulating both antibody production and cellular immunity. Because their core manufacturing process is highly standardized, these vaccines can be produced quickly and at relatively low cost. The large-scale success of mRNA vaccines during the 2019 corona virus pandemic demonstrated their real-world impact. However, several hurdles remain for their broader application. This review summarizes the current state of mRNA modification and packaging for vaccine delivery, the factors that influence administration routes such as intramuscular injection or intravenous infusion, the diverse therapeutic uses of mRNA medicines, and the challenges in evaluating these treatments across different diseases.**

***Index Terms*—mRNA Vaccines, COVID-19 Vaccines, Lipid Nanoparticles, Immunization,**



Figure 1:

I. INTRODUCTION:

RNA therapeutics use specific ribonucleic acid molecules—such as messenger RNA (mRNA) or small interfering RNA (siRNA)—as drugs that act at the genetic level to treat disease. This approach offers a promising alternative to classical pharmaceuticals by directly modulating gene expression, either by silencing problematic genes, replacing faulty ones, or preventing harmful proteins. As evident from the rapid development of COVID-19 vaccines, RNA-based strategies have shown great potential in combating cancer, rare genetic disorders, and infectious diseases. [1] mRNA, in particular, has emerged as a leading platform for vaccines against infections and cancer. Its advantages over conventional vaccines—such as live-attenuated, inactivated, or protein-subunit types—include greater versatility and much faster development timelines. [2] The COVID-19 pandemic shifted mRNA vaccines from niche experimental products to mass-use interventions, with hundreds of millions receiving doses worldwide. Companies such as Moderna and BioNTech rapidly redirected their R&D pipelines to design, test, and deploy mRNA-based vaccines. [3]

II. MECHANISM OF ACTION:

After intramuscular injection, mRNA vaccines enter the body encased in lipid nanoparticles (LNPs), which shield the RNA from degradation and facilitate uptake into cells via endocytosis. Ionizable lipids within the LNPs promote endosomal escape, allowing the mRNA to be released into the cytoplasm, where host ribosomes translate it into protein. [4] In this process, the mRNA is delivered as part of a vaccine formulation in which it is packaged within LNPs to protect it and enhance cellular internalization.[5]

Protein synthesis:

In such vaccines, synthetic mRNA encoding a target antigen—such as the SARS-CoV-2 spike protein—is encapsulated in lipid nanoparticles for stability and efficient delivery into host cells. The LNPs fuse with the cell membrane or are taken up by endocytosis, enabling mRNA to reach the cytoplasm. Once inside, the mRNA does not enter the nucleus; instead, it is directly recognized by host ribosomes. Translation proceeds in three stages: initiation, where the ribosome binds to the 5′ cap and the initiator tRNA

recognizes the start codon; elongation, during which the ribosome moves along the mRNA, and cognate tRNAs bring amino acids to form a growing polypeptide chain; and termination, when a stop codon halts the process and releases the newly synthesized protein antigen. [6] After translation, the protein undergoes post-translational folding and modifications in the endoplasmic reticulum and Golgi apparatus, after which it appears on the cell surface or is secreted into the extracellular environment.

Immune response:

mRNA vaccines elicit both innate and adaptive immune responses. The innate arm is triggered when pattern recognition receptors—such as TLR3, TLR7, and TLR8—recognize structural features of the mRNA. This recognition induces type I interferons and pro-inflammatory cytokines, which act as intrinsic adjuvants and help activate antigen-presenting cells, especially dendritic cells.[6] After delivery, the mRNA is translated within the host cell to produce the encoded antigen. Dendritic cells then internalize or express this antigen, migrate to lymph nodes, and prime T-cell responses. On the adaptive side, activation of $CD4^+$ T helper cells supports B-cell activation, leading to the generation of high-affinity neutralizing antibodies that can block infection. In parallel, $CD8^+$ T-cell responses contribute to cellular immunity against infected or abnormal cells. [6]

III. TYPES OF MRNA VACCINES:

mRNA vaccines are broadly categorized into two main groups: non-replicating (conventional) mRNA vaccines self-amplifying mRNA(saRNA) vaccines, both of which are being explored for preventive and therapeutic immunization. Non replicating mRNA consist of a single stranded mRNA molecule encoding the desired antigen, flanked by key structural elements such as a 5′ cap, untranslated regions (UTRs), an open reading frame (ORF), and a poly(A) tail. Once inside the cell, the mRNA is translated into the target antigen, which then stimulates an immune response. Because this mRNA does not encode its own replication machinery, antigen expression is transient and typically requires higher doses to achieve effective immunogenicity. Despite this, non-replicating mRNA vaccines are widely favored for their conceptual simplicity, safety profile, and ease of large-scale manufacturing. [6, 12, 13]

Self-amplifying mRNA vaccines encode not only the antigen of interest but also viral replicase genes derived from alphaviruses. These replicase proteins enable intracellular amplification of the mRNA, producing multiple copies of the antigen-encoding RNA and thereby increasing both the amount and duration of antigen expression. This amplification allows saRNA vaccines to induce strong immune responses at lower doses than conventional mRNA vaccines. However, the larger size and greater structural complexity of saRNA can complicate stability, delivery, and large-scale production. [6, 12, 13]

IV. ADVANTAGES

mRNA vaccines offer several important advantages over traditional vaccine platforms, making them a game-changing approach in modern vaccinology. One of the most notable benefits is their rapid and flexible design: once the genetic sequence of a target antigen is known, an mRNA vaccine candidate can be generated quickly without the need to culture the pathogen or use complex protein-expression systems. This feature proved critical during the COVID-19 pandemic, where vaccine candidates were designed within weeks of virus sequencing. [6, 7, 8, 10] Because mRNA operates in the cytoplasm and is naturally degraded after translation, it carries no risk of genomic integration and is considered non-infectious, which contributes to a favorable safety profile. mRNA based vaccines also support the induction of both humoral and cellular immunity, including robust activation of $CD4^+$ and $CD8^+$ T cells, due to endogenous antigen synthesis and presentation via major histocompatibility complex molecules. They are highly adaptable and can be readily modified to encode multiple antigens or to target emerging viral variants, making them well suited for rapidly evolving pathogens. The manufacturing process is cell-free and relies on in vitro transcription, which simplifies scale-up and reduces contamination risks. Advanced delivery systems, such as lipid nanoparticles, improve mRNA stability and enhance intracellular delivery. In the case of self-amplifying mRNA platforms, additional benefits include prolonged antigen expression and dose-sparing effects, which may

further strengthen immunogenicity and reduce production costs. [6, 7, 8, 10]

V. LIMITATIONS:

mRNA vaccines face several limitations that may affect their widespread adoption. A major challenge is the need for strict cold-chain conditions, as mRNA is inherently unstable and highly sensitive to ribonuclease-mediated degradation. Early COVID-19 mRNA vaccines required ultra-low-temperature storage (around −70 °C), which posed logistical difficulties, especially in low- and middle-income settings. [14, 15] Although improvements in LNPs and other formulations have enhanced thermal stability, maintaining appropriate storage remains essential for preserving vaccine potency. chemical instability also arises from the single-stranded nature of mRNA, as it is prone to hydrolysis and oxidation, which can impair translational efficiency and shorten shelf life. Another important limitation is the relatively high cost of production and distribution, driven by the need for specialized manufacturing infrastructure, modified nucleosides, advanced lipid carriers, and cold-chain logistics. Scaling up global supply requires sophisticated facilities and stringent quality-control measures, further increasing expenses. Research is actively focused on developing thermostable formulations and more economical production strategies, but these issues continue to pose barriers to equitable global access. [14, 15]

VI. FUTURE PROSPECTS:

The future of mRNA vaccines is highly promising, with expanding applications beyond infectious diseases into personalized medicine, cancer immunotherapy, and other therapeutic areas. In oncology, personalized mRNA vaccines are being designed to target patient-specific tumor neoantigens, derived from genomic sequencing of an individual's cancer. These vaccines aim to generate immune responses that selectively attack malignant cells while largely sparing healthy tissues, paving the way for precision cancer therapy. [16, 17] Beyond cancer, mRNA platforms are being evaluated for vaccines against influenza, HIV, and other emerging viral threats. The flexibility of mRNA allows for rapid adaptation to new variants, as seen with updated COVID-19 vaccines. Efforts are also underway to develop multivalent or combination mRNA vaccines that can simultaneously target multiple pathogens or antigens, improving vaccination coverage and efficiency. Advances in delivery include next-generation lipid nanoparticles, polymer-based carriers, and tissue-targeted delivery systems, all aimed at improving cellular uptake and immune stimulation while minimizing side effects. [16, 17]
Researchers are also exploring thermostable mRNA formulations that can be stored at higher temperatures, which would reduce dependence on cold-chain infrastructure and improve deployment in resource-limited regions. Self-amplifying mRNA and newer RNA platforms, such as circular RNA (circRNA), are being investigated for their ability to sustain antigen expression and enhance stability, potentially enabling lower doses and lower manufacturing costs. In addition, mRNA technology is being applied to protein replacement therapies, correction of genetic disorders, and regenerative medicine. [16, 17]

VII. CONCLUSION

In summary, mRNA vaccines represent a major advance in vaccine science, providing a flexible, rapid, and highly effective platform for preventing and treating a wide range of diseases. Their classification into non-replicating and self-amplifying types reflects the trade-off between simplicity and enhanced immunogenicity .The advantages—such as strong immune responses, good safety, and rapid development—were clearly demonstrated during the COVID-19 pandemic ,[6, 7, 8, 10] Although current challenges related to stability, storage, and cost persist, ongoing research is actively developing improved formulations and delivery systems to address these issues .[14, 15, 16, 17]Looking ahead, the potential applications in personalized medicine, cancer immunotherapy, and emerging infectious diseases highlight the central role that mRNA vaccines are likely to play in the future of global health, positioning them as a cornerstone of next-generation therapeutics and preventive strategies.

REFERENCES:

[1] Chandra S, Wilson JC, Good D, Wei MQ. "mRNA vaccines: a new era in vaccine

development." *Oncol Res.* 2024 Sep 18;32(10):1543.

[2] Trepotec Z, Aneja MK, Geiger J, Hasenpusch G, Plank C, Rudolph C. "Maximizing the translational yield of mRNA therapeutics by minimizing 5'-UTRs." Tissue Eng Part A. 2019; 25:69–79.

[3] Webb C, Ip S, Bathula NV, Popova P, Soriano SK, Ly HH, et al. "Current status and future perspectives on mRNA drug manufacturing." Mol Pharm. 2022 Mar 3;19(4):1047–1058.

[4] Hou X, Zaks T, Langer R, Dong Y. "Lipid nanoparticles for mRNA delivery." Nat Rev Mater. 2021 Dec;6(12):1078–1094.

[5] Chaudhary N, Weissman D, Whitehead KA. "mRNA vaccines for infectious diseases: principles, delivery and clinical translation." Nat Rev Drug Discov. 2021 Nov;20(11):817–838.

[6] Pardi N, Hogan MJ, Weissman D. "Recent advances in mRNA vaccine technology." Curr Opin Immunol. 2020 Aug 1; 65:14–20.

[7] Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. "Developing mRNA-vaccine technologies." RNA Biol. 2012;9(11):1319–1330.

[8] Verbeke R, Lentacker I, De Smedt SC, Dewitte H. "Three decades of messenger RNA vaccine development." Nano Today. 2019; 28:100766.

[9] Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. "The promise of mRNA vaccines: a biotech and industrial perspective." NPJ Vaccines. 2020; 5:11.

[10] Blakney AK, Ip S, Geall AJ. "An update on self-amplifying mRNA vaccine development." Vaccines (Basel). 2021;9(2):97.

[11] Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. "Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses." Mol Ther. 2018;26(2):446–455.

[12] Kallen KJ, Thess A. "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs." Ther Adv Vaccines. 2014;2(1):10–31.

[13] Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. "Addressing the cold reality of mRNA vaccine stability." J Pharm Sci. 2021;110(3):997–1001.

[14] Kis Z, Kontoravdi C, Shattock R, Shah N. "Resources, production scales and time required for producing RNA vaccines for the global pandemic demand." Vaccines (Basel). 2021;9(1):3.

[15] Sahin U, Türeci Ö. "Personalized vaccines for cancer immunotherapy." Science. 2018;359(6382):1355–1360.

[16] Roth GA, Picece VC, Ou BS, Luo W, Pulendran B, Appel EA. "Designing personalized cancer vaccines using RNA technologies." Nat Rev Bioeng. 2022; 1:204–219.

[17] Chen J, Chen J, Xu Q. "Current developments and challenges of mRNA vaccines." Annu Rev Biomed Eng. 2022 Jun 6;24(1):85–109.

[18] Wang YS, Kumari M, Chen GH, Hong MH, Yuan JP, Tsai JL, et al. "mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications." J Biomed Sci. 2023 Oct 7;30(1):84.

[19] Kwon S, Kwon M, Im S, Lee K, Lee H. "mRNA vaccines: the most recent clinical applications of synthetic mRNA." Arch Pharm Res. 2022 Apr;45(4):245–262.

[20] You H, Jones MK, Gordon CA, Arganda AE, Cai P, Al-Wassiti H, et al. "The mRNA vaccine technology era and the future control of parasitic infections." Clin Microbiol Rev. 2023 Mar 23;36(1): e00241-21.

[21] Zhang G, Tang T, Chen Y, Huang X, Liang T. "mRNA vaccines in disease prevention and treatment." Signal Transduct Target Ther. 2023 Sep 20;8(1):365.

[22] Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. "The clinical progress of mRNA vaccines and immunotherapies." Nat Biotechnol. 2022 Jun;40(6):840–854.

[23] Ruiz-Fresneda MA, Ruiz-Pérez R, Ruiz-Fresneda C, Jiménez-Contreras E. "Differences in global scientific production between new mRNA and conventional vaccines against COVID-19." Environ Sci Pollut Res. 2022 Aug;29(38):57054–57066.

[24] Mafuts V. "Emerging trends in vaccine development integrating pharmaceutical science with public health." J Community Health Provision. 2025 Apr 25;5(1):38–49.

[25] Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. "mRNA-based vaccines and therapeutics for COVID-19 and future pandemics." Vaccines. 2022 Dec 15;10(12):2150.

[26] Mohammad W, Al Sayeh A. “mRNA vaccines beyond COVID-19: emerging therapeutic frontiers.” Trends Pharm Biotechnol. 2024 Dec 31;2(2):30–37.
[27] Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. “Tumor vaccination using messenger RNA: prospects of a future therapy.” Curr Opin Immunol. 2011 Jun 1;23(3):399–406.
[28] Wuebben C, Bartok E, Hartmann G. “Innate sensing of mRNA vaccines.” Curr Opin Immunol. 2022 Dec 1; 79:102249.
[29] Hameed SA, Paul S, Dellosa GK, Jaraquemada D, Bello MB. “Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies.” NPJ Vaccines. 2022 Jun 28;7(1):71.
[30] Switzer C, Loeb M. “Evaluating the relationship between myocarditis and mRNA vaccination.” Expert Rev Vaccines. 2022 Jan 2;21(1):83–89.
[31] Zhang C, Maruggi G, Shan H, Li J. “Advances in mRNA vaccines for infectious diseases.” Front Immunol. 2019 Mar 27; 10:594.
[32] Vishweshwaraiah YL, Dokholyan NV. “mRNA vaccines for cancer immunotherapy.” Front Immunol. 2022 Dec 14; 13:1029069.
[33] Zhao J, Liao B, Gong L, Yang H, Li S, Li Y. “Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: a bibliometric and visual analysis.” Hum Vaccin Immunother. 2023 Aug 1;19(2):2254262.
[34] Bowen CM, Sinha KM, Vilar E. “Current trends in vaccine development for hereditary colorectal cancer syndromes.” Clin Colon Rectal Surg. 2024 May;37(03):146–156.
[35] Wu DW, Jia SP, Xing SJ, Ma HL, Wang X, Tang QY, et al. “Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.” Clin Exp Med. 2024 Sep 26;24(1):229.
[36] Miao L, Zhang Y, Huang L. “mRNA vaccine for cancer immunotherapy.” Mol Cancer. 2021 Dec;20(1):41.
[37] Cao LM, Yu YF, Li ZZ, Zhong NN, Wang GR, Xiao Y, et al. “Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.” J Nanobiotechnol. 2024 Jun 2;22(1):308.